Hans-Peter Buchstaller
Overview
Explore the profile of Hans-Peter Buchstaller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Heinrich T, Buchstaller H, Cezanne B, Rohdich F, Bomke J, Friese-Hamim M, et al.
Bioorg Med Chem Lett
. 2016 Dec;
27(3):551-556.
PMID: 27998678
The natural product fumagillin 1 and derivatives like TNP-470 2 or beloranib 3 bind to methionine aminopeptidase 2 (MetAP-2) irreversibly. This enzyme is critical for protein maturation and plays a...
12.
Wucherer-Plietker M, Merkul E, Muller T, Esdar C, Knochel T, Heinrich T, et al.
Bioorg Med Chem Lett
. 2016 May;
26(13):3073-3080.
PMID: 27217002
A combined screening strategy using HTS together with focused kinase library and virtual screening led to the identification of diverse chemical series as PDK1 inhibitors. We focused our medicinal chemistry...
13.
Hoppe E, Hewitt N, Buchstaller H, Eggenweiler H, Sirrenberg C, Zimmermann A, et al.
J Pharm Sci
. 2014 Mar;
103(5):1504-14.
PMID: 24648352
Common strategies to optimize prodrugs use either in vitro or rodent in vivo approaches, which do not consider elimination pathways that do not result in the generation of the desired...
14.
Buchstaller H, Eggenweiler H, Sirrenberg C, Gradler U, Musil D, Hoppe E, et al.
Bioorg Med Chem Lett
. 2012 May;
22(13):4396-403.
PMID: 22632933
Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential molecular therapeutic agents for the treatment of cancer. Here we describe the identification of novel small molecular weight...
15.
Buchstaller H, Burgdorf L, Finsinger D, Stieber F, Sirrenberg C, Amendt C, et al.
Bioorg Med Chem Lett
. 2011 Mar;
21(8):2264-9.
PMID: 21420298
RAF kinase plays a critical role in the RAF-MEK-ERK signaling pathway and inhibitors of RAF could be of use for the treatment of various cancer types. We have designed potent...
16.
Buchstaller H, Anlauf U
Comb Chem High Throughput Screen
. 2010 Dec;
14(2):104-8.
PMID: 21118081
A straightforward and effective procedure for the solution phase preparation of a 2-aminothiazole combinatorial library is described. Reaction, work-up and isolation of the title compounds as free bases was accomplished...
17.
Schiemann K, Finsinger D, Zenke F, Amendt C, Knochel T, Bruge D, et al.
Bioorg Med Chem Lett
. 2010 Feb;
20(5):1491-5.
PMID: 20149654
Here we describe the discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 originally found during a high-throughput screening (HTS) campaign sampling our in-house...
18.
Buchstaller H, Siebert C, Steinmetz R, Frank I, Berger M, Gottschlich R, et al.
J Med Chem
. 2006 Feb;
49(3):864-71.
PMID: 16451052
The standard glycine site antagonist of the N-methyl-D-aspartate (NMDA) receptor, 3-phenyl-4-hydroxyquinolin-2(1H)-one (21), was used as a template for bioisostere benzene/thiophene exchange. Phenylacetylation of aminothiophene carboxylic acid methyl esters and subsequent...
19.
Buchstaller H
J Comb Chem
. 2003 Nov;
5(6):789-93.
PMID: 14606806
The first solid-phase synthesis of oxazolidinones by cycloaddition of resin-bound epoxides with isocyanates is described. Synthesis of the title compounds was achieved by alkylation of resin-bound carbamates with glycidyl tosylate,...